We look forward to working with Richard as we continue to advance ITK inhibition and the unique opportunity it provides to modulate and control parallel signaling pathways in the immune system.” “I am ...

Since 2003, this clinical-stage biopharmaceutical company has focused on the development of cancer peptide vaccines, including its ITK-1 for castration-resistant prostate cancer and GRN-1201 for ...